首页> 外文期刊>Journal of hepato-biliary-pancreatic sciences >Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery
【24h】

Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery

机译:肝切除肝癌肝癌肝癌肝癌肝癌的重要性与门静脉的第一个分支血栓血栓血栓分支:肝脏肝胰腺外科肝脏外科的项目研究

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the major portal vein (PV) is extremely poor. The purpose of this study was to clarify the impact of hepatic resection for HCC with tumor thrombus in the major PV. Patients Four hundred patients undergoing macroscopic curative resection for HCC involving the first branch or trunk of the PV between 2001 and 2010 at the 22 institutions were enrolled. We examined the effect of adjuvant hepatic arterial infusion chemotherapy (HAIC) on prognosis and validated the prognostic index consisting of ascites, prothrombin activity, and maximal tumor diameter. Results Median survival time (MST) and 5‐year overall survival rate were 21.5?months and 25.7%. MST of HAIC group was longer than that of non‐HAIC group (28.1?months vs. 18.7?months, P = 0.0024). Significant prognostic factors for overall survival were PIVKA‐II, tumor diameter, and adjuvant HAIC. MST for patients with prognostic index 0, 1, 2, and 3 was 39.0, 21.1, 18.9, and 5.7?months, respectively ( P = 0.005). Conclusions Macroscopic curative resection with adjuvant HAIC might provide better survival outcome. Furthermore, the prognostic index was useful to select adequate treatment modalities for patients with HCC with tumor thrombosis in the major PV.
机译:摘要背景肝细胞癌(HCC)与肿瘤血栓(PV)患有肿瘤血栓的预后极差。本研究的目的是阐明肝切除对HCC与主要PV肿瘤血栓的影响。患有涉及2001年至2010年在22个机构的2001年至2010年间PV的宏观疗法切割患者患有宏观治疗切除术的患者,均已注册。我们研究了佐剂肝动脉输注化疗(HAIC)对预后的影响,并验证了由腹水,凝血酶原和最大肿瘤直径组成的预后指数。结果中位生存时间(MST)和5年的总生存率为21.5?月份和25.7%。 HAC组的MST比非HAC组(28.1〜30.7个月,18.7个月,P = 0.0024)。整体存活的显着预后因素是PiVKA-II,肿瘤直径和佐剂HAIC。用于预后指数0,1,2和3患者的MST分别为39.0,21.1,18.9和5.7个月(P = 0.005)。结论辅助HAIC宏观治疗切除可能提供更好的存活结果。此外,预后指数可用于选择具有肿瘤血栓形成的HCC患者的足够治疗方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号